Skip to main content
AURX
OTC Industrial Applications And Services

Nuo Q3 Revenue Jumps 81% to $1.87M, But Going Concern Doubt Persists on $81K Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Negative
Importance info
8
Price
$1.09
Mkt Cap
$52.793M
52W Low
$0.77
52W High
$3.23
52W Position info
42% above low
Off High info
66% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

AURX sits 42% above its 52-week low of $0.77 on light trading volume (0.1× avg).

Summary

Nuo Therapeutics grew Q3 revenue 81% to $1.87M and cut its quarterly loss to $424,928, but cash is down to $80,941 and management reiterates substantial doubt about continuing as a going concern, with a Pfizer reagent back order threatening Aurix supply into 2027.


Key Events · Earnings and Guidance · AURX

  • Q3 Revenue Up 81% to $1.87M

    Total revenue was $1,866,125 versus $1,032,096 a year earlier, with product sales of $1,779,563 up from $957,096. Nine-month revenue reached $4,937,226 versus $2,216,679.

  • Loss Narrows but Cash Dwindles

    Q3 net loss was $424,928 versus $537,919; nine-month net loss was $1,320,995 versus $1,933,736. Cash fell to $80,941 at September 30, 2026 from $548,946 at December 31, 2025.

  • Going Concern Doubt Reiterated

    Management states current resources and projected Aurix and Smith+Nephew revenue are insufficient to support operations for the next 12 months, and that substantial doubt about going concern exists.

  • Pfizer Reagent Back Order Threatens Supply

    Thrombin-JMI was on back order by Q3 2026 with resupply estimated for Q2 2027, causing a roughly two-week Aurix stockout in early August 2026; only short-term alternative thrombin supply has been secured.


Analysis · AURX · Industrial Applications And Services

Revenue is compounding fast: Q3 product sales of $1.78M are up 86% year over year, nine-month revenue of $4.94M is up 127%, and the quarterly net loss narrowed to $424,928 from $537,919. The balance sheet, however, is the story. Cash fell to $80,941 from $548,946 at year-end, and management states plainly that current resources plus projected Aurix and Smith+Nephew revenue are insufficient to fund the next 12 months. Funding comes from 12% secured notes, fully drawn at $2.0M after the October 6, 2026 Second Funding, with interest paid in warrants rather than cash and principal amortization starting March 31, 2027. Layered on top is a supply problem: Pfizer's Thrombin-JMI is on back order with resupply estimated for Q2 2027, which caused a roughly two-week Aurix stockout in early August 2026; management says it has short-term alternative thrombin but no long-term solution. The previously disclosed material weakness in internal controls remains unremediated.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AURX was trading at $1.09 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $52.8M. The 52-week trading range was $0.77 to $3.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AURX - Latest Insights

AURX
Aug 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $1.09 info
Change: +$0.320 (+42%) info
Market Cap: $52.793M info
AURX
Aug 17, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $1.09 info
Change: +$0.320 (+42%) info
Market Cap: $52.793M info
AURX
Aug 14, 2026, 5:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.770
Real-time Price: $1.09 info
Change: +$0.320 (+42%) info
Market Cap: $52.793M info
AURX
Jun 03, 2026, 11:04 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $1.09 info
Change: +$0.030 (+3%) info
Market Cap: $52.793M info
AURX
Jun 03, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $1.09 info
Change: +$0.020 (+2%) info
Market Cap: $52.793M info